Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report). Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.
Big Take Home Message from #ACR17 on influenza vaccination- AT Next MTX FUV- give the flu vaccine AND HOLD MTX for 2 weeks (Plenary Session) by Park et al. https://t.co/grfLQx0CYN pic.twitter.com/A3xOyZOu5m
— Dr. John Cush (@RheumNow) November 9, 2017
#ACR17 Rheumatology Roundup.Cush #11L biologics #2 CA; #1175 biologics infants; #141 Refractory RA; #1885 Epi of AOSD; #200 Gout Telemedicine ; #885 Voclosporin SLE GN. AKavanaugh #271 CD318; #1205 XRT OA? #661 Entheses; #1112 Pred Gout; #541 SIE; #2031 EMR labs; #144 MVA RA
— Dr. John Cush (@RheumNow) November 8, 2017
Did you realize that @Twitter now allows all users to send 280-character tweets, doubling the number of allowed characters from 140? This means that you can include twice as much information in your tweets, although I don’t think longer is always better. What do you think? #ACR17
— Jonathan Hausmann MD (@hausmannMD) November 7, 2017